Vimarsana
Biggest News Aggregation in the World

Page 20 - Open Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Open Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Open Access Today - Breaking & Trending Today

About Open Access - Vimarsana News

About Open Access

Under EPW Open Access, authors will have the opportunity to make their published article available at no cost to readers on the EPW website by paying an Open Access Subscription Fee (OASF). Open Access articles will be published under a Creative Commons CC BY 4.0 licence. Why Open Access? broadens the reach of your article increases the possibility of citations may be required by funding organisations benefits the public Requesting Open Access

Source: epw.in
Business News | Impacting Healthcare's Future: Cureus India Symposium Drives Innovation and Collaboration in Medical Research and Publishing - Vimarsana News

Business News | Impacting Healthcare's Future: Cureus India Symposium Drives Innovation and Collaboration in Medical Research and Publishing

Get latest articles and stories on Business at LatestLY. New Delhi [India], March 9: The Cureus Journal of Medical Science, well known for its pioneering open-access publishing platform and part of the Springer Nature Group, successfully concluded its Cureus India Medical Science & Publishing Symposium: Innovating for Tomorrow. The symposium, held in New Delhi on March 7th, 2024, was aimed at addressing the expanding landscape of healthcare research in India. Business News | Impacting Healthcare's Future: Cureus India Symposium Drives Innovation and Collaboration in Medical Resea...

Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study - Vimarsana News

Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study

Objectives To evaluate the added benefit and revenues of oncology drugs, explore their association, and investigate potential discrepancies between added benefit and revenues across different approval pathways of the European Medicines Agency (EMA). Design Retrospective cohort study. Setting Oncology drugs and their indications approved by the EMA between 1995 and 2020. Main outcome measures Added benefit was evaluated using ratings published by seven organisations: health technology assessment agencies from the United States, France, Germany, and Italy, two medical oncology societies, and a d...

Source: bmj.com
Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses - Vimarsana News

Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses

Objective To evaluate the existing meta-analytic evidence of associations between exposure to ultra-processed foods, as defined by the Nova food classification system, and adverse health outcomes. Design Systematic umbrella review of existing meta-analyses. Data sources MEDLINE, PsycINFO, Embase, and the Cochrane Database of Systematic Reviews, as well as manual searches of reference lists from 2009 to June 2023. Eligibility criteria for selecting studies Systematic reviews and meta-analyses of cohort, case-control, and/or cross sectional study designs. To evaluate the credibility of evidence,...

Source: bmj.com
The FOAM Act is dead, but the glass is half full for politically engaged craft brewers - Vimarsana News

The FOAM Act is dead, but the glass is half full for politically engaged craft brewers

Georgia's small craft brewers got a bitter taste of politics at the capitol this session but they say they're gearing up for the next battle.